In which Windtree(WINT) remembers it is a drug company after all, and says something Clinical before lunch A whimsical tale of finance and pharmaceuticals, as told in the Hundred Acre Nasdaq. One day in the Hundred Acre Nasdaq, Windtree the Pooh awoke to a rather curious thing: A press release. It was early, and quite serious. And… Read More »
🌀 Windtree Update: The BNB Play Moves Closer to Reality—Still No Cash In our previous piece, “Is the Answer Blowing in the Windtree?”, we chronicled Windtree Therapeutics’(WINT) recent run of splashy announcements that sounded transformational—crypto treasury strategy, environmental services acquisitions, asset monetizations—but notably, none of them had actually happened yet. Since that article, only one of those… Read More »
Windtree Therapeutics (WINT) has made more announcements in the last six months than many companies do in a decade. But for all the flash and forward-looking language—crypto treasuries, waste management acquisitions, real estate deals, and manufacturing partnerships—there’s one glaring omission: not a single one of these strategies appears to have actually closed, and none are related to… Read More »